QTTB Analyst Ratings
Q32 Bio Inc. (QTTB) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $239.9M, listed on NASDAQ, employing roughly 22 people, carrying a beta of -0.33 to the broader market. Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. Led by Jodie Pope Morrison, public since 2018-03-28.
Analyst Ratings
In the October 2026 monthly count, 6 analysts rated QTTB: 1 Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 3 analysts, 0 Strong Buy, 1 Buy, 2 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $36.50
- Median Target
- $35.00
- High
- $66.00
- Low
- $14.00
- Targets Published, Last 12 Months
- 7
Recent Price Targets
The 5 most recent of 7 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Sep 28, 2026 | Jefferies | Maury Raycroft | $29.00 | $8.77 |
| Aug 24, 2026 | Morgan Stanley | Judah Frommer | $34.00 | $15.97 |
| Jul 28, 2026 | H.C. Wainwright | Joseph Pantginis | $36.00 | $15.21 |
| Jul 13, 2026 | Wells Fargo | Derek Archila | $66.00 | $20.29 |
| Jul 13, 2026 | Oppenheimer | Not named | $40.00 | $20.72 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 13, 2026 | Oppenheimer | maintain | Outperform | Outperform |
| Jul 13, 2026 | Wells Fargo | upgrade | Equal Weight | Overweight |
| May 5, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 12, 2025 | Wells Fargo | maintain | Equal Weight | Equal Weight |
Quantitative Rating
QTTB carries a model grade of A- (overall score 4 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read QTTB Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked QTTB analyst ratings questions
- What is the QTTB consensus price target?
- As of the latest aggregator update, Q32 Bio Inc. (QTTB) carries a consensus 12-month price target of $36.50. Target ranges run from a low of $14.00 to a high of $66.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on QTTB?
- In the October 2026 monthly count, 6 analysts rated QTTB, and the distribution tilts to the Buy side: 1 Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has QTTB seen?
- The five most recent ratings actions on QTTB appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect QTTB options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.